Pelvic Exenteration for Recurrent Vulvar Cancer: A Retrospective Study
Pelvic exenteration (PE) is one of the most radical surgical approaches. In earlier times, PE was associated with high morbidity and mortality. Nowadays, due to improved selection of suitable patients, perioperative settings, and postoperative care, patients’ outcomes have been optimized. To investi...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/16/2/276 |
| _version_ | 1797344476877815808 |
|---|---|
| author | Sabrina Classen-von Spee Saher Baransi Nando Fix Friederike Rawert Verónica Luengas-Würzinger Ruth Lippert Michelle Bonin-Hennig Peter Mallmann Björn Lampe |
| author_facet | Sabrina Classen-von Spee Saher Baransi Nando Fix Friederike Rawert Verónica Luengas-Würzinger Ruth Lippert Michelle Bonin-Hennig Peter Mallmann Björn Lampe |
| author_sort | Sabrina Classen-von Spee |
| collection | DOAJ |
| description | Pelvic exenteration (PE) is one of the most radical surgical approaches. In earlier times, PE was associated with high morbidity and mortality. Nowadays, due to improved selection of suitable patients, perioperative settings, and postoperative care, patients’ outcomes have been optimized. To investigate patients’ outcomes and identify possible influencing clinical and histopathological factors, we analysed 17 patients with recurrent vulvar cancer who underwent PE in our department between 2007 and 2022. The median age was 64.9 years, with a difference of 40 years between the youngest and the oldest patient (41 vs. 81 years). The mean overall survival time was 55.7 months; the longest survival time reached up to 164 months. The achievement of complete cytoreduction (<i>p</i> = 0.02), the indication for surgery (curative vs. palliative), and the presence of distant metastases (both <i>p</i> = 0.01) showed a significant impact on overall survival. The presence of lymphatic metastases (<i>p</i> = 0.11) seems to have an influence on overall survival (OS) time. Major complications appeared in 35% of the patients. Our results support the existing data for PE in cases of recurrent vulvar cancer; for a group of selected patients, PE is a treatment option with good overall survival times and acceptable morbidity. |
| first_indexed | 2024-03-08T11:03:10Z |
| format | Article |
| id | doaj.art-486ec745ad4d42fdb4b86109e28bf11f |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-08T11:03:10Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-486ec745ad4d42fdb4b86109e28bf11f2024-01-26T15:34:53ZengMDPI AGCancers2072-66942024-01-0116227610.3390/cancers16020276Pelvic Exenteration for Recurrent Vulvar Cancer: A Retrospective StudySabrina Classen-von Spee0Saher Baransi1Nando Fix2Friederike Rawert3Verónica Luengas-Würzinger4Ruth Lippert5Michelle Bonin-Hennig6Peter Mallmann7Björn Lampe8Department of Gynecology and Obstetrics, Florence-Nightingale-Hospital, Kreuzbergstraße 79, 40489 Düsseldorf, GermanyDepartment of Gynecology and Obstetrics, Florence-Nightingale-Hospital, Kreuzbergstraße 79, 40489 Düsseldorf, GermanyDepartment of Gynecology and Obstetrics, Florence-Nightingale-Hospital, Kreuzbergstraße 79, 40489 Düsseldorf, GermanyDepartment of Gynecology and Obstetrics, Florence-Nightingale-Hospital, Kreuzbergstraße 79, 40489 Düsseldorf, GermanyDepartment of Gynecology and Obstetrics, Florence-Nightingale-Hospital, Kreuzbergstraße 79, 40489 Düsseldorf, GermanyDepartment of Pathology, Evangelisches Krankenhaus Oberhausen, Virchowstraße 20, 46047 Oberhausen, GermanyDepartment of Gynecology and Obstetrics, Florence-Nightingale-Hospital, Kreuzbergstraße 79, 40489 Düsseldorf, GermanyDepartment of Obstetrics and Gynecology, University of Cologne, Kerpener Str. 62, 50937 Cologne, GermanyDepartment of Gynecology and Obstetrics, Florence-Nightingale-Hospital, Kreuzbergstraße 79, 40489 Düsseldorf, GermanyPelvic exenteration (PE) is one of the most radical surgical approaches. In earlier times, PE was associated with high morbidity and mortality. Nowadays, due to improved selection of suitable patients, perioperative settings, and postoperative care, patients’ outcomes have been optimized. To investigate patients’ outcomes and identify possible influencing clinical and histopathological factors, we analysed 17 patients with recurrent vulvar cancer who underwent PE in our department between 2007 and 2022. The median age was 64.9 years, with a difference of 40 years between the youngest and the oldest patient (41 vs. 81 years). The mean overall survival time was 55.7 months; the longest survival time reached up to 164 months. The achievement of complete cytoreduction (<i>p</i> = 0.02), the indication for surgery (curative vs. palliative), and the presence of distant metastases (both <i>p</i> = 0.01) showed a significant impact on overall survival. The presence of lymphatic metastases (<i>p</i> = 0.11) seems to have an influence on overall survival (OS) time. Major complications appeared in 35% of the patients. Our results support the existing data for PE in cases of recurrent vulvar cancer; for a group of selected patients, PE is a treatment option with good overall survival times and acceptable morbidity.https://www.mdpi.com/2072-6694/16/2/276recurrent vulvar cancerpelvic exenterationoverall survivalcomplicationsp53p16/HPV |
| spellingShingle | Sabrina Classen-von Spee Saher Baransi Nando Fix Friederike Rawert Verónica Luengas-Würzinger Ruth Lippert Michelle Bonin-Hennig Peter Mallmann Björn Lampe Pelvic Exenteration for Recurrent Vulvar Cancer: A Retrospective Study Cancers recurrent vulvar cancer pelvic exenteration overall survival complications p53 p16/HPV |
| title | Pelvic Exenteration for Recurrent Vulvar Cancer: A Retrospective Study |
| title_full | Pelvic Exenteration for Recurrent Vulvar Cancer: A Retrospective Study |
| title_fullStr | Pelvic Exenteration for Recurrent Vulvar Cancer: A Retrospective Study |
| title_full_unstemmed | Pelvic Exenteration for Recurrent Vulvar Cancer: A Retrospective Study |
| title_short | Pelvic Exenteration for Recurrent Vulvar Cancer: A Retrospective Study |
| title_sort | pelvic exenteration for recurrent vulvar cancer a retrospective study |
| topic | recurrent vulvar cancer pelvic exenteration overall survival complications p53 p16/HPV |
| url | https://www.mdpi.com/2072-6694/16/2/276 |
| work_keys_str_mv | AT sabrinaclassenvonspee pelvicexenterationforrecurrentvulvarcanceraretrospectivestudy AT saherbaransi pelvicexenterationforrecurrentvulvarcanceraretrospectivestudy AT nandofix pelvicexenterationforrecurrentvulvarcanceraretrospectivestudy AT friederikerawert pelvicexenterationforrecurrentvulvarcanceraretrospectivestudy AT veronicaluengaswurzinger pelvicexenterationforrecurrentvulvarcanceraretrospectivestudy AT ruthlippert pelvicexenterationforrecurrentvulvarcanceraretrospectivestudy AT michelleboninhennig pelvicexenterationforrecurrentvulvarcanceraretrospectivestudy AT petermallmann pelvicexenterationforrecurrentvulvarcanceraretrospectivestudy AT bjornlampe pelvicexenterationforrecurrentvulvarcanceraretrospectivestudy |